image dons

I make a donation

ADRIFT

Searching the rivaroxaban dosis which enables an adequate anticoagulation evaluated by the level of thrombin generated in patients suffering atrial fibrillation and having a successful percutaneous left atrial appendage closure.

Terminée

Colloquium : Pathologies cardiaques de la femme (15 novembre 2022)
Présentations en ligne !!!

logo étude

objectif

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure

date de réalisation

2017

nombre de patients

84

nombre de centres participants

National multicentric trial

type de financement

Public (APHP) & Private (Bayer)

Référence

NCT03273322

A study conducted by Fonds de Dotation ACTION
Find out details and results on the dedicated page

ADRIFT conducted by Fonds de Dotation ACTION

Autres études

+

ABYSS

En cours


Phase 4 trial, evaluating the interest of betablocking treatment in the long term treatment of non-complicated myocardial infarct.
+

EDUC-DAI

En cours


Impact of therapeutic education on the quality of life and the anxiety of patients with a defibrillator.
+

ACORES-2

En cours


Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.